KOMBITEST CD3 FITC / CD19 PE

Cat.No. ED7053

1. Intended purpose

The KOMBITEST CD3 FITC / CD19 PE is designed for percentage enumeration of mature human T and B lymphocytes in erythrocyte-lysed whole blood using Flow Cytometry.

2. Test principle

This test is based on the specific binding of monoclonal antibodies to the antigenic determinants expressed on the surface of leukocytes. The monoclonal antibodies are labeled with different fluorochromes which are excited via laser beam from a flow cytometer during analysis. Subsequent emissions of light from the fluorochromes of each cell are collected and analyzed by a flow cytometer. The fluorescence intensity differences enable the separation of cell subsets based on the expression of analyzed antigens. The specific staining of blood cells is performed

The specific staining of blood cells is performed by the incubation of blood samples with the reagent followed by a lysis of red blood cells. Afterwards, unaffected leukocytes are subjected to analysis by a flow cytometer.

3. Reagents provided

The reagent contains a premixed combination of mouse monoclonal antibody against human CD3 antigen (clone UCHT1) labeled with Fluorescein isothiocyanate (FITC), and mouse monoclonal antibody against human CD19 antigen (clone 4G7) labeled with R-phycoerythrin (PE). Labeled antibodies are diluted at optimum concentration in stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide. The content of a vial (1 mI) is sufficient for 50 tests.

Product specification

o a a o i op o ooa		
Content	50 tests, 1 ml	
Usage	20 µl per test	
Specificity	CD3	CD19
Clone	UCHT1	4G7
Isotype (mouse)	lgG1	lgG1
Fluorochrome	FITC	PE
λ excitation	488 nm	488 nm
Emission maximum	525 nm	575 nm

4. Materials required but not provided

Test tubes for blood staining (e.g. 12 × 75 mm) Commercial lysing solution PBS buffer

5. Equipment required

Automatic pipettes with disposable tips

Vortex mixer Centrifuge

Flow cytometer with excitation laser 488 nm and proper filters

6. Storage and handling

Store the vial at 2-8°C. Keep away from sunlight. Do not freeze. Do not aliquot. Expiration date is stated on a vial label and on

Expiration date is stated on a vial label and on outer packaging.

- 7. Warnings, precautions and limitations of use
- Intended for In Vitro Diagnostic use in laboratories outside USA and Canada. This CE-IVD reagent is in conformity with the European Directive 98/79/EC.
- Do not use reagent after expiration date.
- Avoid reagents contamination.
- Avoid prolonged exposure to light.The content of the vial must not freeze.
- The flow cytometer should be calibrated on a routine basis using fluorescent microbeads to
- Any non-performance of the staining protocol may produce false results.
- The reagent contains sodium azide (NaN₃) which is highly toxic in pure form. However, the concentration in the reagent (15mM) is not considered as hazardous. When disposing the reagent, flush the sink with a large volume of water.
- Concentrations of labeled antibodies in this reagent were optimized to offer the best specific signal/non-specific signal ratio. Therefore, it is important to adhere to the reagent volume/sample volume ratio in every test. Do not dilute the reagent.
- Do not use reagent volumes other than specified in this IFU.
- Blood samples are considered as potentially infectious and must be handled with care.

Avoid all contact of the sample with the skin, eyes and mucosa.

- In case of a hyperleukocytose sample, it is recommended to dilute the blood sample with PBS to obtain leukocyte density approximately 5 × 10⁶ leukocytes/ml.
- Blood samples from abnormal patients may exhibit abnormal values of positive cells.
- Data may be incorrectly interpreted if fluorescent signals were compensated wrongly or if gates were positioned inaccurately.
- Flow cytometer may produce false results if the device has not been aligned and maintained appropriately.

8. Specimen

Use the peripheral human blood in a sterile tube with an anticoagulant (Heparin or EDTA). Blood must be stored at room temperature.

Use the blood sample no later than 48 hours after collection.

9. Procedure

Staining protocol


- 1. Add 20 μ l of KOMBITEST CD3 FITC / CD19 PE reagent to a test tube.
- Add 100 μl of blood sample to the tube. Vortex the tube.
 Incubate the tube for 15-20 minutes at room
- Incubate the tube for 15-20 minutes at room temperature in the dark.
 Perform lysis of red cells using commercial
- I choin yas on ted status damp commercial lysing solution containing formaldehyde as a fixative. Follow the instructions of the lysing solution manufacturer.
 Centrifuge tubes for 5 minutes at 300 g.
- Centralige tubes for 5 minutes at 300 g.
 Remove supernatant and resuspend pellet with 3-4 ml of PBS.
- Centrifuge tubes for 5 minutes at 300 g.
 Remove supernatant and resuspend pellet with 0.1–0.5 ml of PBS.
- Analyze the sample immediately using a flow cytometer or store sample at 2-8°C in the dark and analyze within 24 hours provided that cells were fixed.

Flow Cytometric Analysis

Analyze stained samples using a flow cytometer equipped with excitation laser 488 nm and proper filters. Compensate fluorescent signals prior to or after data accuisition.


prior to or after data acquisition. Visualize compensated data on the side-scatter (SSC) versus forward-scatter (FSC) plot. Set the gate for lymphocyte population as shown in figure 1. Alternatively, set the optimal lymphocyte gate using KOMBITEST CD45 FITC / CD14 PE (refer the datasheet for lymphocyte gate assessment procedure).

Fig. 1: Delimitation of lymphocyte population



Then make a CD3 FITC versus CD19 PE dot-plot of lymphocyte population as shown in figure 2. Separate populations using appropriate gate and calculate the percentage of T lymphocytes situated in lower-right quadrant (CD3+CD19-) and B lymphocytes situated in upper-left quadrant (CD3-CD19+) on the dot-plot.

Fig. 2: Lymphocytes in a dot-plot CD3 FITC vs. CD19 PE



10. Analytical performance

Specificity


The antibody UCHT1 recognizes the CD3 antigen of the TCR/CD3 complex on mature human T cells. The UCHT1 antibody reacts with the epsilon chain of the CD3 complex (HLDA I WS Code: T 3, HLDA III WS Code: T 126, HLDA III WS Code: T 471, HLDA VI WS Code: T 6T-CD3.1).

The mouse monoclonal antibody 4G7 recognizes CD19 (B4), a 95 kDa type I transmembrane glycoprotein of immunoglobulin superfamily, expressed on B lymphocytes and follicular dendritic cells; it is lost on plasma cells (HLDA: WS Code 2 B43).


Accuracy

The accuracy of the method was studied by the comparison of KOMBITEST with competitor's product in parallel staining of 43 blood samples. The regression analysis is given below.

Regression Analysis of CD3+/CD19- Lymphocytes





Regression Analysis of CD3⁻/CD19⁺ Lymphocytes



Linearity

The linearity of the method was determined on 10 serial dilutions of leukocyte-enriched blood sample (buffy coat). Cell samples were stained by KOMBITEST in triplicates. Measured and expected values were expressed in terms of absolute count (cells/µl) in graphs given below. Range of CD3+CD19-Lymphocytes





Repeatability

The repeatability of the assay was measured on stabilized blood sample (Immuno-Troll[™] Cells, Beckman-Coulter) in ten tubes in parallel. Coefficients of variation (CV) are given in the table below.

Lymphocyte Subset	n	AVG	SD	cv
CD3+CD19- (%)	10	70.3	0.94	1.34
CD3-CD19+ (%)	10	14.5	1.36	9.37

Reproducibility

The reproducibility of the assay was measured on stabilized blood sample (Immuno-Troll[™] Cells, Beckman-Coulter) under the same conditions for four weeks. Coefficients of variation (CV) are given in the table below.

given in the table be	low.			
Lymphocyte Subset	n	AVG	SD	с٧
CD3+CD19- (%)	14	72.7	0.97	1.34
CD3-CD19+ (%)	14	13.2	1.16	8.78

11. Clinical performance

Expected values

Results obtained in different laboratories may vary. Each laboratory should establish a normal range of cell subsets using its own test conditions. Results obtained in our laboratory are given in the table below.

Lymphocyte Subset	n	Mean	95% Range
CD3+CD19- (%)	108	71	52-83
CD3+CD19- (cells/µl)	54	1480	886-2341
CD3-CD19+ (%)	108	13	5-24
CD3-CD19+ (cells/µl)	54	242	87-445

12. References

Alarcón B, Swamy M, van Santen HM, Schamel WW: T-cell antigen-receptor stoichiometry: preclustering for sensitivity. EMBO Rep. 2006 May;7(5):490-5.

Arnett KL, Harrison SC, Wiley DC: Crystal structure of a human CD3-epsilon/delta dimer in complex with a UCHT1 single-chain antibody fragment. Proc Natl Acad Sci U S A. 2004 Nov 16;101(46):16268-73.

Barclay, Brown et al.: The Leukocyte Antigen FactsBook, 2nd edition, Harcourt Brace & Company, London, (1997).

Dubois B, Massacrier C, Caux C: Selective attraction of naive and memory B cells by dendritic cells. J Leukoc Biol. 2001 Oct;70(4):633-41.

Huang Y, Wange RL: T cell receptor signaling: beyond complex complexes. J Biol Chem. 2004 Jul 9;279(28):28827-30.

Kuhns MS, Davis MM, Garcia KC: Deconstructing the form and function of the TCR/CD3 complex. Immunity. 2006 Feb;24(2):133-9.

Leukocyte Typing III., McMichael A. J. et al (Eds.), Oxford University Press (1987).

Leukocyte Typing VI., Kishimoto T. et al. (Eds.), Garland Publishing Inc. (1997).

Rieux-Laucat F, Hivroz C, Lim A, Mateo V, Pellier I, Selz F, Fischer A, Le Deist F: Inherited and somatic CD3zeta mutations in a patient with Tcell deficiency. N Engl J Med. 2006 May 4;354(18):1913-21.

Siegers GM, Swamy M, Fernández-Malavé E, Minguet S, Rathmann S, Guardo AC, Pérez-Flores V, Regueiro JR, Alarcón B, Fisch P, Schamel WW: Different composition of the human and the mouse gammadelta T cell receptor explains different phenotypes of CD3gamma and CD3delta immunodeficiencies. J Exp Med. 2007 Oct 29;204(11):2537-44.

Torres PS, Alcover A, Zapata DA, Arnaud J, Pacheco A, Martín-Fernández JM, Villasevil EM, Sanal O, Regueiro JR: TCR dynamics in human mature T lymphocytes lacking CD3 gamma. J Immunol. 2003 Jun 15;170(12):5947-55.

13. Manufacturer

EXBIO Praha, a.s. Nad Safinou II 341 25250 Vestec Czech Republic

info@exbio.cz

technical@exbio.cz orders@exbio.cz www.exbio.cz

14. Trademarks

Immuno-Troll[™] Cells is registered trademark of Beckman-Coulter.

15. Revision History

• Version 1, ED7053_IFU_v1 Initial Release

 Version 2 ED7053 IEU v2 The text removed in in the reagent provided: "0.2% (w/v) high-grade protease free Bovine Serum Albumin (BSA) as a stabilizing agent." Version 3, ED7053_IFU_v3 Version 3, ED/OS3_IFU_V3
 The company logo changed. IFU layout changed.
 "Keep away from sunlight", "Do not aliquot" added in Storage section. Texts "Do not dilute the reagent" and "Do not use reagent volumes other than specified in this IFU" were added in

warning section. Postal code changed:" 25250 Vestec"



KOMBITEST CD3 FITC / CD19 PE

50 tests | Cat.No. ED7053



Instructions for Use

Version: ED7053_IFU_v3_EN Date of Issue: 10-11-2020

Symbols

REF	Catalogue number
LOT	Batch code
\square	Use-by date
X	Temperature limits
漛	Keep away from sunlight
IVD	In vitro diagnostic medical device
CE	CE marking of conformity
ĺ	Consult instructions for use
***	Manufacturer

The product is intended for In Vitro Diagnostic Use. In vivo diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or

as a manufacture component of another product without written conset of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s..